Ken Griffin Io Biotech, Inc. Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.17 - $1.71 $33,078 - $48,345	28,272 Added 48.23%	86,894 $101,000
Q1 2024 May 15, 2024	BUY	$1.48 - $1.99 $9,997 - $13,442	6,755 Added 13.02%	58,622 $101,000
Q4 2023 Feb 14, 2024	BUY	$0.84 - $1.95 $43,568 - $101,140	51,867 New	51,867 $97,000
Q2 2023 Aug 14, 2023	SELL	$1.61 - $2.19 $14,734 - $20,042	-9,152 Reduced 19.54%	37,690 $73,000
Q1 2023 May 15, 2023	BUY	$1.88 - $2.98 $88,062 - $139,589	46,842 New	46,842 $88,000
Q3 2022 Nov 14, 2022	BUY	$2.51 - $4.85 $69,662 - $134,606	27,754 Added 192.39%	42,180 $114,000

23.6M

Ticker IOBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,815,300
Market Cap $22.2M
Description
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in ph...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.